NCT02561039View on ClinicalTrials.gov

A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Pain; Bone Neoplasms; Neoplasm Metastasis
Interventions
DRUG

Ibandronate

Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.

Trial Locations (9)

1757

Sofia

1784

Sofia

3000

Vratsa

4004

Plovdiv

5800

Pleven

6300

Haskovo

8000

Burgas

9002

Varna

9010

Varna

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02561039 - A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease | Biotech Hunter | Biotech Hunter